Clear­side Bio­med­ical pre­dicts its uveitis drug will be re­ject­ed, af­ter FDA re­quests more da­ta

In its sec­ond-quar­ter up­date ear­li­er this month, eye drug de­vel­op­er Clear­side Bio­med­ical in­di­cat­ed it was look­ing to out-li­cense its lead drug, Xipere, which is cur­rent­ly …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.